Search results
1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?
Motley Fool via Yahoo Finance· 7 days agoClinical-stage biotech Editas Medicine (NASDAQ: EDIT) delivered quarterly results that fell well...
Director Jessica Hopfield Acquires 45,000 Shares of Editas Medicine Inc (EDIT)
GuruFocus.com via Yahoo Finance· 2 days agoOn May 13, 2024, Jessica Hopfield, Director at Editas Medicine Inc (NASDAQ:EDIT), purchased 45,000...
Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest...
Simply Wall St. via Yahoo Finance· 4 days agoEditas Medicine, Inc. (NASDAQ:EDIT) just released its latest quarterly report and things are not...
Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 7 days agoEditas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript May 8, 2024 Editas Medicine,...
Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down
Zacks via Yahoo Finance· 7 days agoEditas Medicine, Inc. EDIT incurred a loss of 76 cents per share in the first quarter of 2024, wider...
CRISPR can treat common form of inherited blindness, early data hint
Live Science via Yahoo News· 21 hours agoA photo shows two male doctors in surgery garb as one preps a long needle for a procedure. A patient...
Gene Editing Breakthrough: CRISPR Improves Vision in Clinical Trial
SciTechDaily· 3 days agoMass Eye and Ear researchers say their findings support continued research and clinical trials of...
How Editas 'dragged' Linda Burkly over as CSO after 37 years at Biogen
FierceBiotech· 6 days agoLinda Burkly, Ph.D., was 37 years into a career at Biogen when Editas Medicines CEO Gilmore...
CRISPR-based gene editing treatment shows promise for rare eye disorder
MedicalNewsToday via AOL· 7 days agoResearchers at Oregon Health & Science University used an experimental CRISPR-based gene editing...